GlassScriptPhysician profile
Kamal K Dutta
NPI 1952433062
$53,204.66
in general payments reported to CMS, 2019-2025
14 companies · $1,020 in 2025
The $1,020 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $332 · 2022: $456 · 2023: $51K · 2024: $623 · 2025: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $50K · Food and Beverage: $2,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $50,000.00 |
| Food and Beverage | $2,417.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spectra Medical Devices, LLC | $50,000.00 | 2023 | Numstat Antiseptic and Pain Relieving Prep Pad |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $691.81 | 2021-2024 | Xifaxan, Trulance |
| Intra-Sana Laboratories | $689.13 | 2022-2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Gilead Sciences, INC. | $470.18 | 2021-2025 | Vemlidy, Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $365.09 | 2023-2024 | Zeposia |
| Boston Scientific Corporation | $150.00 | 2023 | Watchman Flx |
| Ipsen Biopharmaceuticals, INC | $139.29 | 2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $125.00 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $124.97 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $123.41 | 2021 | |
| Novo Nordisk INC | $121.15 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $119.03 | 2022 | |
| Madrigal Pharmaceuticals | $70.45 | 2025 | Rezdiffra |
| Micro-Tech Endoscopy USA, INC. | $15.15 | 2023 | Dat Closure Device |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Dutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.